Interferon-γ is produced by another player of innate immune responses: The interferon-producing killer dendritic cell (IKDC)

Biochimie

Volumn 89, Issue 6-7, 2007, Pages 872-877

  Bonmort, Mathieu ^a,b   Ullrich, Evelyn ^a   Mignot, Grégoire ^a,b   Jacobs, Bénédikt ^a   Chaput, Nathalie ^a,c   Zitvogel, Laurence ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

c kit tyrosine kinase inhibitor; Dendritic cells; Imatinib mesylate; Interferon ; Interferon producing killer dendritic cells; Interleukin 2; TNF related apoptosis inducing ligand; Tumor immunity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IMATINIB; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG MEGADOSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INNATE IMMUNITY; LUNG METASTASIS; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; TUMOR CELL;

ANIMALS; ANTIGENS, CD45; ANTIGENS, SURFACE; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34347220864     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.04.014     Document Type: Article

References (32)

1. Zitvogel L., Casares N., Pequignot M.O., Chaput N., Albert M.L., and Kroemer G. Immune response against dying tumor cells. Adv. Immunol. 84 (2004) 131-179
2. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., and Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107-1111
3. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., Maruyama K., Wakasugi H., Angevin E., Thielemans K., Le Cesne A., Chung-Scott V., Lazar V., Tchou I., Crepineau F., Lemoine F., Bernard J., Fletcher J.A., Turhan A., Blay J.Y., Spatz A., Emile J.F., Heinrich M.C., Mecheri S., Tursz T., and Zitvogel L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114 (2004) 379-388
4. Taieb J., Chaput N., Menard C., Apetoh L., Ullrich E., Bonmort M., Pequignot M., Casares N., Terme M., Flament C., Opolon P., Lecluse Y., Metivier D., Tomasello E., Vivier E., Ghiringhelli F., Martin F., Klatzmann D., Poynard T., Tursz T., Raposo G., Yagita H., Ryffel B., Kroemer G., and Zitvogel L. A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12 (2006) 214-219
5. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 (2006) 715-727
6. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18 (1997) 175-182
7. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., and Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12 (1994) 337-365
8. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
9. Inaba K., Metlay J.P., Crowley M.T., and Steinman R.M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J. Exp. Med. 172 (1990) 631-640
10. Diefenbach A., Jensen E.R., Jamieson A.M., and Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
11. Smyth M.J., Swann J., Kelly J.M., Cretney E., Yokoyama W.M., Diefenbach A., Sayers T.J., and Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200 (2004) 1325-1335
12. Smyth M.J., Takeda K., Hayakawa Y., Peschon J.J., van den Brink M.R., and Yagita H. Nature's TRAIL-on a path to cancer immunotherapy. Immunity 18 (2003) 1-6
13. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., and Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189 (1999) 1451-1460
14. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
15. Street S.E., Cretney E., and Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001) 192-197
16. Cretney E., Takeda K., Yagita H., Glaccum M., Peschon J.J., and Smyth M.J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168 (2002) 1356-1361
17. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., and Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195 (2002) 161-169
18. Fanger N.A., Maliszewski C.R., Schooley K., and Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190 (1999) 1155-1164
19. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., and Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189 (1999) 1343-1354
20. Ghiringhelli F., Menard C., Puig P.E., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., and Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25 (+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2006) 641-648
21. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., Coutant F., Metivier D., Pichard E., Aucouturier P., Pierron G., Garrido C., Zitvogel L., and Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005) 1691-1701
22. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Metivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., and Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007) 54-61
23. Ullrich E., Bonmort M., Mignot G., Chaput N., Taieb J., Menard C., Viaud S., Tursz T., Kroemer G., and Zitvogel L. Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res. 67 (2007) 851-853
24. Chan C.W., Crafton E., Fan H.N., Flook J., Yoshimura K., Skarica M., Brockstedt D., Dubensky T.W., Stins M.F., Lanier L.L., Pardoll D.M., and Housseau F. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12 (2006) 207-213
25. Spits H., and Lanier L.L. Natural killer or dendritic: what's in a name?. Immunity 26 (2007) 11-16
26. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., and Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95 (2004) 777-783
27. Vremec D., O'Keeffe M., Hochrein H., Fuchsberger M., Caminschi I., Lahoud M., and Shortman K. Production of interferons by dendritic cells, plasmacytoid cells, natural killer cells and interferon-producing killer dendritic cells. Blood 109 (2007) 1165-1173
28. Shortman K., and Villadangos J.A. Is it a DC, is it an NK? No, it's an IKDC. Nat. Med. 12 (2006) 167-168
29. Welner R.S., Pelayo R., Garrett K.P., Chen X., Perry S.S., Sun X.H., Kee B.L., and Kincade P.W. Interferon-producing killer dendritic cells (IKDC) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood 109 (2007) 4825-4931
30. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6 (2006) 836-848
31. Ibe S., Qin Z., Schuler T., Preiss S., and Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J. Exp. Med. 194 (2001) 1549-1559
32. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., Yagita H., and Okumura K. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193 (2001) 661-670